HAE stock icon

Haemonetics
HAE

$73.24
1.8%

Market Cap: $3.75B

 

About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Employees: 3,657

0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

872% more call options, than puts

Call options by funds: $37.2M | Put options by funds: $3.83M

64% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 33

9.17% more ownership

Funds ownership: 100.44% [Q1] → 109.61% (+9.17%) [Q2]

7% more funds holding

Funds holding: 295 [Q1] → 316 (+21) [Q2]

6% more capital invested

Capital invested by funds: $4.35B [Q1] → $4.62B (+$267M) [Q2]

5% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 107

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$85
16%
upside
Avg. target
$108
47%
upside
High target
$125
71%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Citigroup
Joanne Wuensch
66% 1-year accuracy
25 / 38 met price target
16%upside
$85
Neutral
Maintained
22 Aug 2024
JMP Securities
David Turkaly
59% 1-year accuracy
16 / 27 met price target
71%upside
$125
Market Outperform
Reiterated
13 Aug 2024
Barrington Research
Michael Petusky
62% 1-year accuracy
31 / 50 met price target
47%upside
$108
Outperform
Maintained
9 Aug 2024
Needham
Mike Matson
64% 1-year accuracy
72 / 113 met price target
53%upside
$112
Buy
Upgraded
12 Jun 2024

Financial journalist opinion

Based on 8 articles about HAE published over the past 30 days